ALINT IntegraGen SA
IntegraGen SA provides researchers with sequencing solutions, data management tools, and biostatistical, and bioinformatics support services in France. The company's genomic pharma services DNA sequencing for oncology and rare disease research; and NGS testing for cancer research. It also provides MERCURY, an online biological interpretation tool for oncology intended to assist pathologists and oncologists in transforming raw data obtained through high-throughput sequencing into a molecular report for translational and clinical research use; and GeCo, a genomic consulting service that offers researchers with access to biostatistics and bioanalytics experts. IntegraGen SA was incorporated in 2000 and is headquartered in Évry, France. IntegraGen SA operates as a subsidiary of OncoDNA SA.…
Industry Peers
BiotechnologyKey Statistics
About IntegraGen (EPA: ALINT)
›
IntegraGen (EPA: ALINT) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 27 employees.
The shares were at 0.0750 EUR on 18 November 2026, down 42.3% over 52 weeks. Its 52-week range is 0.0130 EUR to 0.3610 EUR: the price is 79.2% below the high and 476.9% above the low.
Its market capitalisation is 491.77K EUR.
IntegraGen reports return on equity of -8.5%, an operating margin of -56.3% and revenue down 27.9% year over year.
Its debt exceeds its cash by 130.20K EUR, a debt-to-equity ratio of 0.56. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.